Summary
Kenvue, the maker of Tylenol, saw its stock drop sharply after reports that U.S. Health Secretary Robert F. Kennedy Jr. might suggest a link between Tylenol use during pregnancy and autism. The company denied any causal link and emphasized that leading medical organizations agree on the safety of acetaminophen during pregnancy. Kenvue recommends that pregnant women consult healthcare professionals before taking any medication.
Key Facts
- Kenvue's stock fell 14% before ending the day down 9.5%.
- RFK Jr. is expected to propose a potential connection between Tylenol use in pregnancy and autism.
- The U.S. Department of Health and Human Services called the report's claims speculative.
- Tylenol is a widely recommended pain reliever for pregnant women in the U.S., preferred over ibuprofen.
- Medical bodies like the American College of Obstetricians and Gynecologists see no clear evidence linking acetaminophen to developmental issues.
- Autism affects around one in 31 children in the U.S., with ongoing research into potential causes.
- Some studies report a link between acetaminophen use in pregnancy and increased autism risk, but findings are inconclusive.
- Kenvue continues to maintain that acetaminophen is safe when used as directed during pregnancy.
